Lupin is currently trading at Rs. 911.60, up by 19.80 points or 2.22% from its previous closing of Rs. 891.80 on the BSE.
The scrip opened at Rs. 896.00 and has touched a high and low of Rs. 914.00 and Rs. 892.25 respectively. So far 157219 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 914.40 and Rs. 877.70 respectively. The current market cap of the company is Rs. 41239.88 crore.
The promoters holding in the company stood at 46.91%, while Institutions and Non-Institutions held 40.21% and 12.60% respectively.
Lupin has received approval for its Penicillamine Tablets USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Depen Tablets, 250 mg, of Mylan Specialty, L.P. The product would be manufactured at Lupin’s Nagpur facility and is expected to be launched shortly.
Penicillamine Tablets USP, 250 mg, are indicated in the treatment of Wilson’s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.55 |
Dr. Reddys Lab | 6217.15 |
Cipla | 1405.40 |
Zydus Lifesciences | 953.50 |
Lupin | 1589.10 |
View more.. |